Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (pts) with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Rosenberg, J. E.; Heath, E.; Perez, R.; Merchan, J.; Lang, J.; Ruether, D.; Petrylak, D.; Sangha, R.; Smith, D. C.; Sridhar, S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Suppression of oncogene transcription - PNA as targeted cancer therapy for BRAF-V600E mutant melanoma
    Meeting Abstract

    Rothman, J. H.; Surriga, O.; Ambrosini, G.; Vasudeva, S.; Schwartz, G. K.
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Impact of AR-V7 protein localization in the prediction of therapeutic benefit of taxanes over androgen receptor signaling inhibitors (ARSi) in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H.; Graf, R.; Schreiber, N.; Lu, D.; Louw, J.; Alvarez, H. A. V.; Bambury, R.; Danila, D.; McLaughlin, B.; Heller, G.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors
    Meeting Abstract

    Segal, N. H.; Infante, J. R.; Sanborn, R. E.; Gibney, G. T.; Lawrence, D. P.; Rizvi, N.; Leidner, R.; Gajewski, T. F.; Bertino, E.; Sharfman, W. H.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort
    Meeting Abstract

    Segal, N. H.; Ou, S. H. I.; Balmanoukian, A. S.; Massarelli, E.; Brahmer, J. R.; Weiss, J.; Schoffski, P.; Antonia, S. J.; Massard, C.; Zandberg, D. P.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Updated results from PROFILE 1001
    Meeting Abstract

    Shaw, A.; Riley, G. J.; Bang, Y. J.; Kim, D. W.; Camidge, D. R.; Varella-Garcia, M.; Lafrate, A. J.; Shapiro, G.; Winter, M.; Usari, T.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Anti-tumor activity of PEGylated human IL-10 (AM0010) in renal cancer alone and in combination with anti-PD1
    Meeting Abstract

    Naing, A.; Papadopoulos, K. P.; Autio, K. A.; Ott, P. A.; Patel, M. R.; Wong, D. J.; Falchook, G.; Pant, S.; Whiteside, M.; Rasco, D.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Nomogram-based prediction of overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (UC) receiving first-line platinum-based chemotherapy: Retrospective international study of invasive/advanced cancer of the urothelium (RISC)
    Meeting Abstract

    Necchi, A.; Sonpavde, G.; Lo Vullo, S.; Bamias, A.; Crabb, S. J.; Harshman, L.; Bellmunt, J.; De Giorgi, U.; Sternberg, C.; Ladoire, S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • A phase II trial investigating the highly selective c-Met inhibitor tepotinib in stage IIIB/IV lung adenocarcinoma with MET exon 14 alterations after failure of at least one prior therapy
    Meeting Abstract

    Paik, P. K.; Stammberger, U.; Bruns, R.
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Rociletinib-associated cataracts in EGFR-mutant NSCLC
    Meeting Abstract

    Piotrowska, Z.; Liu, E.; Varga, A.; Thakur, M.; Narayanan, V.; Liu, S. V.; Neal, J.; Spiegel, M.; Solomon, B.; Yu, H.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save